phenylalanine and melphalan

phenylalanine has been researched along with melphalan in 70 studies

Research

Studies (70)

Timeframe	Studies, this research(%)	All Research%
pre-1990	37 (52.86)	18.7374
1990's	2 (2.86)	18.2507
2000's	2 (2.86)	29.6817
2010's	9 (12.86)	24.3611
2020's	20 (28.57)	2.80

Authors

Authors	Studies
Crooks, PA; Matharu, J; Oki, J; Smith, QR; Worthen, DR	1
Borisov, VI	1
Ren, YF; Zheng, YY	1
Begleiter, A; Goldenberg, GJ; Lam, HY; Lee, M	1
Rabinovitz, M; Toal, JN; Vistica, DT	1
Greig, NH; Purdon, D; Rapoport, SI; Smith, QR; Takada, Y; Vistica, DT	1
Cornford, EM; Finlay, GJ; Pardridge, WM; Paxton, JW; Wilson, WR; Young, D	1
Presant, CA; Serpick, AA; Wiernik, PH	1
Cheliapov, NV; Doronina, TN; Gorin, AI; Tseĭtlin, PI	1
Hosoya, K; Morimoto, Y; Nozaki, S; Ogawa, Y; Sugibayashi, K; Sugihara, S	1
Liang, HZ; Xu, B; Zhou, JX	1
Harada, N; Hata, H; Matsuno, F; Matsuzaki, H; Mitsuya, H; Nagasaki, A	1
Audus, KL; Hirano, K; Hirose, F; Kupczyk-Subotkowska, L; Ryu, T; Sakaeda, T; Siahaan, TJ; Stella, VJ; Sugawara, T; Tada, Y; Yoshikawa, T	1
KHOKHLOV, AS; LARIONOV, LF; NOVIKOVA, MA; SHKODINSKAJA, EN; TROOSHEIKINA, VI; VASINA, OS	1
ZHDANOV, GL	1
CHEBOTAREVA, LI	1
SELIGER, H	1
KURAHORI, T; YAMAGUCHI, H; YOSHIMURA, Y	1
SOROKINA, IB	1
LARIONOV, LF	1
PEREVODCHIKOVA, NI	1
CASTELLANO, M; LOVISETTO, P	1
TRUSHEIKINA, VI	2
GALTON, DA; PAPAC, R; TILL, M; WILTSHAW, E	1
ALTENBURG, E; ALTENBURG, LS	1
LUCK, JM	1
DAVYDOVA, SIa; SAPOZHNIKOVA, MB	1
AUSTIN, C; BERGSAGEL, DE; GRIFFITH, KM; SPRAGUE, CC	1
BLAZEK, J; KRACMAR, J	1
DIDDLE, AW; JENKINS, HH; WATTS, G; WATTS, J	1
BARCELO, P; PUIGDOLLERS, JM; SANS-SABRAFEN, J	1
CLARK, RL; SMITH, JL; STEHLIN, JS	1
ACTON, EM; BERRIDGE, BJ; GOODMAN, L; GRAM, HF	1
ACTON, EM; GOODMAN, L; IWAMOTO, RH; MOSHER, CW	1
KLATT, O; MILNER, AN; STEHLIN, JS; YOUNG, SE	1
BELOUSOVA, AK; IVANOVA, TJ	1
DAO, TL; GRINBERG, R; NEMOTO, T	1
KHOKHLOV, AS; LARIONOV, LF; NOVIKOVA, MA; SKHODINSKAIA, EN; TRUSHEIKINA, VL; VASINA, OS	1
LARIONOV, LF; PEREVODCHIKOVA, NI	1
BRUNA, T; DARGENT, M; POMMATAU, E	1
Anderson, KC; Chauhan, D; Lewensohn, R; Munshi, N; Paba-Prada, C; Ray, A; Richardson, P; Spira, J; Viktorsson, K	1
Dale, T; Fryknäs, M; Fuchs, PF; Gerwins, P; Gullbo, J; Larsson, R; Strese, S; Wickström, M	1
HSU, TC; STUBBLEFIELD, E	1
Alvfors, C; Berglund, Å; Gullbo, J; Hagberg, H; Harmenberg, J; Jerling, M; Lewensohn, R; Lisyanskaya, A; Nordström, E; Nygren, P; Orlov, S; Ringbom, M; Söderlind, K; Spira, J; Tholander, B; Ullén, A	1
Hååg, P; Holmsten, K; Juntti, T; Kanter, L; Lewensohn, R; Shah, CH; Sierakowiak, A; Spira, J; Tu, J; Ullén, A; Viktorsson, K; Zielinska-Chomej, K	1
Delforoush, M; Enblad, G; Gullbo, J; Larsson, R; Strese, S; Wickström, M	1
Anderson, KC; Chauhan, D; Das, DS; Gullbo, J; Nordström, E; Ravillah, D; Ray, A; Richardson, PG; Song, Y	1
Carlier, C; Ceelen, WP; De Vlieghere, E; Gullbo, J; Juntti, T; Larsson, R; Lewensohn, R; Nygren, P; Spira, J; Strese, S; Uustalu, M; Velander, E; Viktorsson, K	1
Gullbo, J; Haglund, C; Hassan, SB; Höglund, M; Larsson, R; Strese, S; Velander, E	1
Aschan, J; Pour, L; Robak, P; Schjesvold, F; Sonneveld, P	1
Anderson, K; Bringhen, S; Byrne, C; Chauhan, D; Harmenberg, J; Mellqvist, UH; Nordström, E; Paba-Prada, C; Palumbo, A; Plesner, T; Reeves, B; Richardson, PG; Sonneveld, P; Voorhees, P; Zubair, H	1
Asbjarnarson, A; Bergthorsson, JT; Gudjonsson, T; Ingthorsson, S; Joelsson, JP; Kricker, J; Lehmann, F; Nupponen, N; Schepsky, A; Slipicevic, A; Traustadottir, GA	1
Gullbo, J; Hajek, R; Hassoun, H; Larocca, A; Leleu, X; Oriol, A; Paner, A; Richardson, PG; Rodríguez-Otero, P; Schjesvold, FH	1
Alegre, A; Anderson, KC; Bakker, NA; Bladé, J; Byrne, C; Cavo, M; Harmenberg, J; Hassoun, H; Hiemenz, JW; Larocca, A; Laubach, JP; Leleu, X; Maisel, C; Mateos, MV; Mazumder, A; Moreb, JS; Nadeem, O; Oriol, A; Paner, A; Raptis, A; Richardson, PG; Rodriguez-Otero, P; Thuresson, M; Thuresson, S; Touzeau, C	1
Bringhen, S; Byrne, C; Harmenberg, J; Mellqvist, UH; Nordström, E; Obermüller, J; Plesner, T; Reeves, B; Richardson, PG; Sonneveld, P; Voorhees, PM	1
Hillengass, J; Holstein, SA; McCarthy, PL	1
Al-Janazreh, H; Canale, FA; Cutrona, G; D'Arrigo, G; Gentile, M; Martino, EA; Martino, M; Mendicino, F; Morabito, F; Morabito, L; Neri, A; Todoerti, K; Tripepi, G; Vigna, E	1
Lehmann, F; Lindberg, J; Nilvebrant, J; Nygren, PÅ	1
Banerjee, R; Goodman, A; Kelkar, AH; Midha, S; Mohyuddin, GR; Prasad, V	1
Jessee, JK	1
Gonsalves, WI; Kapoor, P	1
Alekseeva, Y; Bakker, NA; Byrne, C; Coriu, D; Delimpasi, S; Dimopoulos, MA; Doronin, V; Hájek, R; Harmenberg, J; Lazzaro, A; Legiec, W; Liberati, AM; Maisnar, V; Masszi, T; Mateos, MV; Mikala, G; Minarik, J; Moody, V; Pour, L; Richardson, PG; Robak, P; Rosiñol, L; Salogub, G; Schjesvold, FH; Sonneveld, P; Špička, I; Symeonidis, A; Thuresson, M	1
Bakker, NA; Schjesvold, FH; Sonneveld, P	1
Hadidi, SA	1
Emeh, P; Eskelinen, A; Gebraad, A; Heckman, CA; Kuismanen, K; Lehmann, F; Manninen, M; Miettinen, JJ; Miettinen, S; Nupponen, NN; Ohlsbom, R; Pakarinen, TK; Slipicevic, A	1
Dimopoulos, MA; Gay, F; Mateos, MV; Nadeem, O; Ocio, EM; Richardson, PG; Schjesvold, F; Touzeau, C	1
Efebera, YA; Larocca, A; Leleu, X; Mateos, MV; Nadeem, O; Paner, A; Richardson, PG; Rodríguez-Otero, P	1
Acs, K; Diao, Y; Färnegårdh, K; Färnegårdh, M; Fasth, KJ; Hammer, K; Lehmann, F; Svensson Gelius, S; Westermark, U	1
Cliff, ERS; Janakiram, M; Kesselheim, AS	1

Reviews

6 review(s) available for phenylalanine and melphalan

Article	Year
Soviet antitumor preparations. National Cancer Institute monograph, 1977, Issue:45 Topics: Animals; Antineoplastic Agents; Aziridines; Butylated Hydroxytoluene; Dactinomycin; Daunorubicin; Humans; Melphalan; Methylnitrosourea; Neoplasms, Experimental; Nitrogen Mustard Compounds; Olivomycins; Organophosphorus Compounds; Phenylalanine; Prospidium; Pyrimidines; Spiro Compounds; Streptonigrin; Tegafur; Triethylenephosphoramide; Uracil	1977
Melflufen for relapsed and refractory multiple myeloma. Expert opinion on investigational drugs, 2020, Volume: 29, Issue:10 Topics: Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Humans; Melphalan; Multiple Myeloma; Phenylalanine; Recurrence; Survival Rate	2020
Spotlight on Melphalan Flufenamide: An Up-and-Coming Therapy for the Treatment of Myeloma. Drug design, development and therapy, 2021, Volume: 15 Topics: Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Drug Resistance, Neoplasm; Humans; Melphalan; Multiple Myeloma; Phenylalanine	2021
Progress and Future Directions with Peptide-Drug Conjugates for Targeted Cancer Therapy. Molecules (Basel, Switzerland), 2021, Oct-05, Volume: 26, Issue:19 Topics: Antineoplastic Agents; Cytotoxins; Drug Carriers; Drug Delivery Systems; Drug Design; Humans; Immunoconjugates; Melphalan; Neoplasms; Peptides; Pharmaceutical Preparations; Phenylalanine; Radiotherapy; Somatostatin	2021
Pepaxto: A New Peptide-Drug Conjugate for Heavily Pretreated Relapsed and Refractory Multiple Myeloma. The Annals of pharmacotherapy, 2022, Volume: 56, Issue:8 Topics: Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Humans; Melphalan; Multiple Myeloma; Peptides; Phenylalanine	2022
Melphalan flufenamide for relapsed/refractory multiple myeloma. Drugs of today (Barcelona, Spain : 1998), 2022, Volume: 58, Issue:8 Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Humans; Melphalan; Multiple Myeloma; Phenylalanine	2022

Trials

6 trial(s) available for phenylalanine and melphalan

Article	Year
First-in-human, phase I/IIa clinical study of the peptidase potentiated alkylator melflufen administered every three weeks to patients with advanced solid tumor malignancies. Investigational new drugs, 2015, Volume: 33, Issue:6 Topics: Adult; Aged; Aged, 80 and over; Alkylation; Antineoplastic Agents, Alkylating; Disease Progression; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Hematologic Diseases; Humans; Male; Melphalan; Middle Aged; Neoplasms; Peptide Hydrolases; Phenylalanine; Prospective Studies	2015
OCEAN: a randomized Phase III study of melflufen + dexamethasone to treat relapsed refractory multiple myeloma. Future oncology (London, England), 2020, Volume: 16, Issue:11 Topics: Antineoplastic Combined Chemotherapy Protocols; Clinical Trials, Phase III as Topic; Dexamethasone; Drug Resistance, Neoplasm; Humans; Lenalidomide; Melphalan; Multiple Myeloma; Phenylalanine; Progression-Free Survival; Randomized Controlled Trials as Topic; Recurrence; Thalidomide	2020
Melflufen plus dexamethasone in relapsed and refractory multiple myeloma (O-12-M1): a multicentre, international, open-label, phase 1-2 study. The Lancet. Haematology, 2020, Volume: 7, Issue:5 Topics: Aged; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Disease-Free Survival; Female; Humans; Kaplan-Meier Estimate; Male; Maximum Tolerated Dose; Melphalan; Middle Aged; Multiple Myeloma; Neoplasm Recurrence, Local; Phenylalanine	2020
Melflufen and Dexamethasone in Heavily Pretreated Relapsed and Refractory Multiple Myeloma. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2021, 03-01, Volume: 39, Issue:7 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Disease Progression; Drug Resistance, Neoplasm; Europe; Female; Humans; Male; Melphalan; Middle Aged; Multiple Myeloma; Phenylalanine; Progression-Free Survival; Recurrence; Time Factors; United States	2021
Melflufen plus dexamethasone in relapsed/refractory multiple myeloma: long-term survival follow-up from the Phase II study O-12-M1. British journal of haematology, 2021, Volume: 193, Issue:6 Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Disease-Free Survival; Female; Follow-Up Studies; Humans; Male; Melphalan; Middle Aged; Multiple Myeloma; Phenylalanine; Survival Rate	2021
Melflufen or pomalidomide plus dexamethasone for patients with multiple myeloma refractory to lenalidomide (OCEAN): a randomised, head-to-head, open-label, phase 3 study. The Lancet. Haematology, 2022, Volume: 9, Issue:2 Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; COVID-19 Drug Treatment; Dexamethasone; Female; Humans; Lenalidomide; Male; Melphalan; Middle Aged; Multiple Myeloma; Phenylalanine; SARS-CoV-2; Thalidomide	2022

Other Studies

58 other study(ies) available for phenylalanine and melphalan

Article	Year
Regiospecific and conformationally restrained analogs of melphalan and DL-2-NAM-7 and their affinities for the large neutral amino acid transporter (system LAT1) of the blood-brain barrier. Bioorganic & medicinal chemistry letters, 2010, Jun-15, Volume: 20, Issue:12 Topics: Animals; Biological Transport; Blood-Brain Barrier; Brain; Large Neutral Amino Acid-Transporter 1; Melphalan; Molecular Conformation; Molecular Structure; Myeloablative Agonists; Norbornanes; Protein Binding; Rats; Structure-Activity Relationship	2010
[Tumour chemotherapy. XXXIX Synthesis of 2-methyl-5-bis (beta-chloroethyl) aminophenylalanine and 2-bis (beta-chloroethyl)-aminomethyl-5-nitrophenylalanine (author's transl)]. Yao xue xue bao = Acta pharmaceutica Sinica, 1979, Volume: 14, Issue:11 Topics: Animals; Antineoplastic Agents; Melphalan; Mice; Neoplasms; Nitrogen Mustard Compounds; Phenylalanine	1979
Evidence for carrier-mediated transport of melphalan by L5178Y lymphoblasts in vitro. Cancer research, 1977, Volume: 37, Issue:3 Topics: Antimetabolites; Biological Transport, Active; Carrier Proteins; Cells, Cultured; Kinetics; Lymphocytes; Lymphoma; Melphalan; Neoplasms, Experimental; Phenylalanine; Sodium; Temperature	1977
Amino acid-conferred resistance to melphalan. I. Structure-activity relationship in cultured murine L1210 leukemia cells. Cancer treatment reports, 1976, Volume: 60, Issue:9 Topics: Amino Acids; Animals; Cells, Cultured; Drug Interactions; Drug Resistance; Glutamine; Leucine; Leukemia L1210; Melphalan; Mice; Phenylalanine; Structure-Activity Relationship	1976
Rapid high-affinity transport of a chemotherapeutic amino acid across the blood-brain barrier. Cancer research, 1992, Apr-15, Volume: 52, Issue:8 Topics: 2-Naphthylamine; Animals; Blood-Brain Barrier; Brain; Male; Melphalan; Nitrogen Mustard Compounds; Phenylalanine; Rats	1992
Melphalan penetration of the blood-brain barrier via the neutral amino acid transporter in tumor-bearing brain. Cancer research, 1992, Jan-01, Volume: 52, Issue:1 Topics: Amino Acid Transport Systems; Animals; Biological Transport; Blood-Brain Barrier; Carcinoma 256, Walker; Carrier Proteins; Melphalan; Phenylalanine; Rats	1992
Effects of phenylalanine and related compounds on serum alkaline phosphatase assay. Clinica chimica acta; international journal of clinical chemistry, 1971, Volume: 32, Issue:3 Topics: Adult; Alkaline Phosphatase; Bone Diseases; Chemistry, Clinical; Chloramphenicol; Fenclonine; Humans; Liver Diseases; Melphalan; Neoplasms; Phenylalanine; Phenylketonurias; Stereoisomerism	1971
[Effect of embichin and sarcolysin on the structure of total histone]. Biulleten' eksperimental'noi biologii i meditsiny, 1971, Volume: 72, Issue:10 Topics: Animals; Cattle; Histones; Mechlorethamine; Melphalan; Optical Rotatory Dispersion; Phenylalanine; Spectrophotometry; Thymus Gland; Viscosity	1971
Antitumor agent poly (amino acid) conjugates as a drug carrier in cancer chemotherapy. Journal of pharmacobio-dynamics, 1984, Volume: 7, Issue:9 Topics: Absorption; Alkylating Agents; Animals; Carrier Proteins; Delayed-Action Preparations; Injections, Subcutaneous; Melphalan; Peptides; Phenylalanine; Polyglutamic Acid; Polylysine; Rats; Rats, Inbred Strains; Sarcoma, Yoshida	1984
[Antitumor action of phenylalanine derivatives of mechlorethamine (author's transl)]. Zhongguo yao li xue bao = Acta pharmacologica Sinica, 1981, Volume: 2, Issue:2 Topics: Animals; Antineoplastic Agents; Melphalan; Mice; Neoplasms, Experimental; Nitrogen Mustard Compounds; Phenylalanine; Rats; Structure-Activity Relationship	1981
Down-regulation of CD98 in melphalan-resistant myeloma cells with reduced drug uptake. Acta haematologica, 2000, Volume: 103, Issue:3 Topics: Antigens, CD; Antigens, Neoplasm; Antineoplastic Agents, Alkylating; ATP Binding Cassette Transporter, Subfamily B, Member 1; ATP-Binding Cassette Transporters; Biological Transport; Carrier Proteins; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Ethyl Methanesulfonate; Fusion Regulatory Protein-1; Gene Expression Regulation, Neoplastic; Glutamate-Cysteine Ligase; Humans; Melphalan; Multidrug Resistance-Associated Proteins; Multiple Myeloma; Mutagenesis; Neoplasm Proteins; Phenylalanine; Structure-Activity Relationship; Tumor Cells, Cultured; Vault Ribonucleoprotein Particles	2000
Conjugation with L-Glutamate for in vivo brain drug delivery. Journal of drug targeting, 2001, Volume: 9, Issue:1 Topics: Animals; Antineoplastic Agents, Alkylating; Blood-Brain Barrier; Brain; Capillary Permeability; Drug Delivery Systems; Drug Evaluation; Endorphins; Glutamic Acid; Kynurenic Acid; Male; Melphalan; Phenylalanine; Prodrugs; Rats; Rats, Wistar	2001
Studies on the anti-tumour activity of p-di-(2-chloroethyl) aminophenylalanine (sarcolysine). Lancet (London, England), 1955, Jul-23, Volume: 269, Issue:6882 Topics: Melphalan; Neoplasms; Phenylalanine; Sarcoma; Sarcoma, Experimental	1955
[Effect of sarcolysin on proliferating tissue]. Voprosy onkologii, 1955, Volume: 1, Issue:6 Topics: Animals; Melphalan; Neoplasms, Experimental; Phenylalanine	1955
[Experience in treating seminoma of the testes and its metastases with sarcolysin]. Voprosy onkologii, 1956, Volume: 2, Issue:3 Topics: Dysgerminoma; Female; Humans; Male; Melphalan; Neoplasms; Neoplasms, Germ Cell and Embryonal; Ovarian Neoplasms; Phenylalanine; Seminoma; Testicular Neoplasms; Testis	1956
[A new chemotherapeutic agent for control of malignant tumors: p-di-(-2-chloroethyl)-aminophenylanine (sarcolysine)]. Der Krebsarzt, 1956, Volume: 11, Issue:6 Topics: Antineoplastic Agents; Humans; Melphalan; Neoplasms; Phenylalanine	1956
[On the effects of sarcolysine on the Yoshida sarcoma and sarcoma 180]. Gan, 1956, Volume: 47, Issue:3-4 Topics: Animals; Melphalan; Neoplasms, Experimental; Phenylalanine; Sarcoma 180; Sarcoma, Yoshida	1956
[Lowered action of sarcolysin on hemopoiesis in rabbits following preliminary administration of colchicine]. Biulleten' eksperimental'noi biologii i meditsiny, 1957, Volume: 43, Issue:1 Topics: Animals; Antineoplastic Agents; Colchicine; Hematopoiesis; Hematopoietic System; Melphalan; Pharmaceutical Preparations; Phenylalanine; Rabbits	1957
Experimental results with sarcolysine. Acta - Unio Internationalis Contra Cancrum, 1957, Volume: 13, Issue:3 Topics: Animals; Antineoplastic Agents; Breast Neoplasms; Humans; Mammary Neoplasms, Experimental; Melphalan; Phenylalanine	1957
Some results of the clinical use of sarcolysine (dl-p-dl/2-chlorethyl/aminophenil-alanin-chlorhydrate). Acta - Unio Internationalis Contra Cancrum, 1957, Volume: 13, Issue:3 Topics: Antineoplastic Agents; Melphalan; Phenylalanine	1957
[P-bis-(beta-chloroethyl) aminophenylalanine (sarcolysin) in antiblastic chemotherapy with special reference to lymphatic blood diseases]. Haematologica, 1958, Volume: 43, Issue:4 Topics: Hodgkin Disease; Humans; Leukemia; Lymphoma, Large B-Cell, Diffuse; Lymphoma, Non-Hodgkin; Mechlorethamine; Melphalan; Multiple Myeloma; Nitrogen Mustard Compounds; Phenylalanine; Plasma Cells; Sarcoma	1958
[Anti-tumor activity of optic isomers of sarcolysin]. Biulleten' eksperimental'noi biologii i meditsiny, 1958, Volume: 46, Issue:9 Topics: Isomerism; Mechlorethamine; Melphalan; Neoplasms; Nitrogen Mustard Compounds; Phenylalanine	1958
Preliminary clinical trial of p-di-2-chloroethyl-amino-L-phenylalanine (CB 3025, melphalan) and of di-2-chloroethyl methanesulfonate (CB 1506). Annals of the New York Academy of Sciences, 1958, Apr-24, Volume: 68, Issue:3 Topics: Antineoplastic Agents; Humans; Mechlorethamine; Melphalan; Mesylates; Nitrogen Mustard Compounds; Phenylalanine	1958
Ratio of visible to lethal mutations produced in Drosophila by phenylalanine mustard. Nature, 1959, Mar-07, Volume: 183, Issue:4662 Topics: Animals; Chromosomes; Drosophila; Mechlorethamine; Melphalan; Mutation; Nitrogen Mustard Compounds; Phenylalanine	1959
Further observations on the efficacy of phenylalanine mustards against mouse melanoma. Cancer research, 1961, Volume: 21 Topics: Animals; Mechlorethamine; Melanoma, Experimental; Melphalan; Mice; Nitrogen Mustard Compounds; Phenylalanine	1961
[The effect of sarcolysin and dopan on the biosynthesis of pyrimidines of nucleic acid in transplanted tumors and tissues of the recipient organism]. Biulleten' eksperimental'noi biologii i meditsiny, 1960, Volume: 49 Topics: Mechlorethamine; Melphalan; Neoplasms; Neoplasms, Experimental; Nitrogen Mustard Compounds; Nucleic Acids; Phenylalanine; Pyrimidines; Uracil Mustard	1960
Evaluation of new chemotherapeutic agents in the treatment of multiple myeloma. IV. L-Phenylalanine mustard (NSC-8806). Cancer chemotherapy reports, 1962, Volume: 21 Topics: Antineoplastic Agents; Cell- and Tissue-Based Therapy; Melphalan; Multiple Myeloma; Mustard Plant; Phenylalanine; Plasma; Plasma Cells	1962
[Spectrophotometric determination of D,L-p-di-(beta-chloroethyl)-aminophenylalanine chloride (Sarcolysin) in the ultraviolet spectrum]. Ceskoslovenska farmacie, 1962, May-05, Volume: 11 Topics: Chlorides; Ions; Melphalan; Phenylalanine; Spectrophotometry	1962
Nitrogen and phenylalanine mustard. Use in women with intrauterine cancer. American journal of obstetrics and gynecology, 1962, Feb-15, Volume: 83 Topics: Female; Humans; Mechlorethamine; Melphalan; Neoplasms; Nitrogen; Nitrogen Mustard Compounds; Phenylalanine; Uterine Neoplasms	1962
[di-(2-chloroethyl)amino]-L-phenylalanine ("Melphalan")]. Revista espanola de reumatismo y enfermedades osteoarticulares, 1962, Volume: 9 Topics: Humans; Melphalan; Multiple Myeloma; Phenylalanine	1962
HISTOPATHOLOGICAL CHANGES IN MALIGNANT MELANOMA AND NORMAL TISSUES FOLLOWING REGIONAL PERFUSION WITH L-PHENYLALANINE MUSTARD (L-SARCOLYSIN). Acta - Unio Internationalis Contra Cancrum, 1964, Volume: 20 Topics: Chemotherapy, Cancer, Regional Perfusion; Extracorporeal Circulation; Lymphatic Metastasis; Melanoma; Melphalan; Mice; Mustard Plant; Neoplasms; Neoplasms, Experimental; Pharmacology; Phenylalanine; Research	1964
POTENTIAL ANTICANCER AGENTS. LXXX. ALKYLATING AGENTS RELATED TO PHENYLALANINE MUSTARD. VI. ENANTIOMERIC META-PHENYLALANINE MUSTARDS. Journal of medicinal chemistry, 1963, Volume: 6 Topics: Alkylating Agents; Animals; Antineoplastic Agents; Carcinoma 256, Walker; Carcinoma, Hepatocellular; Chemistry, Pharmaceutical; Leukemia; Leukemia, Experimental; Liver Neoplasms; Lung Neoplasms; Melphalan; Neoplasms, Experimental; Nitrogen Mustard Compounds; Pharmacology; Phenylalanine; Research; Skin Neoplasms	1963
POLYPEPTIDES FROM P-PHENYLALANINE MUSTARD. Journal of medicinal chemistry, 1964, Volume: 7 Topics: Animals; Carcinoma; Carcinoma 256, Walker; Chemistry, Pharmaceutical; Leukemia L1210; Melphalan; Mice; Nitrogen Mustard Compounds; Peptides; Pharmacology; Phenylalanine; Rats; Research; Sarcoma 180; Toxicology	1964
THE BIOCHEMICAL MECHANISM OF ACTION OF L-PHENYLALANINE MUSTARD. I. DISTRIBUTION OF L-PHENYLALANINE MUSTARD-H3 IN TUMOR-BEARING RATS. Cancer research, 1965, Volume: 25 Topics: Animals; Bone Marrow; Carcinoma 256, Walker; Chromatography; DNA; Intestines; Kidney; Liver; Melphalan; Metabolism; Muscles; Mustard Plant; Neoplasms; Pharmacology; Phenylalanine; Plasma; Rats; Research; Spleen; Thymus Gland; Tritium; Tyrosine	1965
ON THE MECHANISM OF SARCOLYSIN FIXATION BY PROTEINS OF TUMOUR CELLS. Acta - Unio Internationalis Contra Cancrum, 1964, Volume: 20 Topics: Animals; Autoradiography; Carbon Isotopes; Carcinoma, Ehrlich Tumor; Chloramphenicol; Culture Media; DNA; DNA, Neoplasm; Female; Humans; Melphalan; Ovarian Neoplasms; Pharmacology; Phenylalanine; Proteins; Research; RNA; RNA, Neoplasm; Sarcoma; Sarcoma, Experimental	1964
L-PHENYLALANINE MUSTARD (NSC-8806) IN UNCOMMON MALIGNANT DISEASE IN CHILDREN. Cancer chemotherapy reports, 1965, Volume: 45 Topics: Child; Humans; Melphalan; Mustard Plant; Neoplasms; Phenylalanine; Toxicology	1965
[ANTINEOPLASTIC ACTIVITY OF O-BIS(2-CHLOROETHYL) AMINO-DL-PHENYLALANINE (ORTHOSARCOLYSIN)]. Voprosy onkologii, 1964, Volume: 10 Topics: Antineoplastic Agents; Melphalan; Neoplasms; Neoplasms, Experimental; Pharmacology; Phenylalanine; Rats; Research; Toxicology	1964
[Anti-tumor action of p-bis (chloroethyl) aminophenylalanine (sarcolysin)]. Biulleten' eksperimental'noi biologii i meditsiny, 1955, Volume: 39, Issue:1 Topics: Animals; Melphalan; Neoplasms; Neoplasms, Experimental; Phenylalanine	1955
Some experimental and clinical data on the sarcolysin peptides. British medical journal, 1960, Jan-09, Volume: 1, Issue:5166 Topics: Melphalan; Neoplasms; Peptides; Phenylalanine	1960
[Action of sarcolysin in a case of testicular tumor with pulmonary metastases showing the "balloon release" image]. Lyon medical, 1960, Feb-02, Volume: 92 Topics: Humans; Lung Neoplasms; Male; Melphalan; Patient Discharge; Phenylalanine; Testicular Neoplasms	1960
In vitro and in vivo antitumor activity of a novel alkylating agent, melphalan-flufenamide, against multiple myeloma cells. Clinical cancer research : an official journal of the American Association for Cancer Research, 2013, Jun-01, Volume: 19, Issue:11 Topics: Angiogenesis Inhibitors; Animals; Antineoplastic Agents, Alkylating; Cell Line, Tumor; Cell Movement; Cell Survival; Disease Models, Animal; Drug Synergism; Female; Humans; Melphalan; Mice; Multiple Myeloma; Neovascularization, Pathologic; Phenylalanine; Tumor Burden; Xenograft Model Antitumor Assays	2013
The novel alkylating prodrug melflufen (J1) inhibits angiogenesis in vitro and in vivo. Biochemical pharmacology, 2013, Oct-01, Volume: 86, Issue:7 Topics: Alkylating Agents; Angiogenesis Inhibitors; Animals; Cattle; CD13 Antigens; Chick Embryo; Chorioallantoic Membrane; Drug Screening Assays, Antitumor; Human Umbilical Vein Endothelial Cells; Melphalan; Mice; Neovascularization, Pathologic; Phenylalanine; Prodrugs	2013
Effect of phenylalanine nitrogen mustard on tissues in culture. Antibiotics & chemotherapy (Northfield, Ill.), 1957, Volume: 7, Issue:9 Topics: Immunologic Tests; Mechlorethamine; Melphalan; Nitrogen Mustard Compounds; Phenylalanine; Research Design; Tissue Culture Techniques	1957
Melphalan-flufenamide is cytotoxic and potentiates treatment with chemotherapy and the Src inhibitor dasatinib in urothelial carcinoma. Molecular oncology, 2016, Volume: 10, Issue:5 Topics: Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; bcl-2 Homologous Antagonist-Killer Protein; bcl-2-Associated X Protein; Cell Line, Tumor; Dasatinib; Humans; Melphalan; Phenylalanine; Protein Kinase Inhibitors; src-Family Kinases; Urologic Neoplasms; Urothelium	2016
In vitro and in vivo activity of melflufen (J1)in lymphoma. BMC cancer, 2016, Apr-04, Volume: 16 Topics: Animals; Cell Line, Tumor; Cell Proliferation; G2 Phase Cell Cycle Checkpoints; Humans; Lymphoma; Melphalan; Mice; Multiple Myeloma; Phenylalanine; Xenograft Model Antitumor Assays	2016
A novel alkylating agent Melflufen induces irreversible DNA damage and cytotoxicity in multiple myeloma cells. British journal of haematology, 2016, Volume: 174, Issue:3 Topics: Antineoplastic Agents, Alkylating; Apoptosis; DNA Damage; DNA Repair; Drug Resistance, Neoplasm; Histones; Humans; Kinetics; Melphalan; Multiple Myeloma; Phenylalanine; Phosphorylation; Signal Transduction; Tumor Cells, Cultured	2016
Preclinical activity of melflufen (J1) in ovarian cancer. Oncotarget, 2016, Sep-13, Volume: 7, Issue:37 Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Cell Line, Tumor; Cytoreduction Surgical Procedures; Disease-Free Survival; Drug Evaluation, Preclinical; Female; Humans; Hyperthermia, Induced; Injections, Intraperitoneal; Melphalan; Mice; Mice, SCID; Neoplasm Recurrence, Local; Neoplasm Staging; Ovarian Neoplasms; Peritoneal Neoplasms; Phenylalanine; Xenograft Model Antitumor Assays	2016
In vitro and in vivo anti-leukemic activity of the peptidase-potentiated alkylator melflufen in acute myeloid leukemia. Oncotarget, 2017, Jan-24, Volume: 8, Issue:4 Topics: Animals; Antigens, CD34; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Daunorubicin; Dose-Response Relationship, Drug; Drug Synergism; Female; HL-60 Cells; Humans; Inhibitory Concentration 50; Leukemia, Myeloid, Acute; Male; Melphalan; Mice, SCID; Middle Aged; Neoplastic Stem Cells; Phenylalanine; Time Factors; Tumor Cells, Cultured; Xenograft Model Antitumor Assays	2017
Melflufen, a peptide-conjugated alkylator, is an efficient anti-neo-plastic drug in breast cancer cell lines. Cancer medicine, 2020, Volume: 9, Issue:18 Topics: Animals; Antineoplastic Agents, Alkylating; Breast Neoplasms; CD13 Antigens; Cell Line, Tumor; Chick Embryo; Dipeptidyl-Peptidases and Tripeptidyl-Peptidases; DNA Damage; Female; Gene Expression Regulation, Neoplastic; Histones; Humans; Leucyl Aminopeptidase; Melphalan; Phenylalanine; Signal Transduction; Tumor Suppressor p53-Binding Protein 1	2020
Melflufen: A Next-Generation Nitrogen Mustard. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2021, 03-01, Volume: 39, Issue:7 Topics: Animals; Antineoplastic Agents, Alkylating; Humans; Melphalan; Multiple Myeloma; Phenylalanine; Treatment Outcome	2021
Synthetic control arms in studies of multiple myeloma and diffuse large B-cell lymphoma. British journal of haematology, 2022, Volume: 196, Issue:5 Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Immunological; Biological Products; Clinical Trials as Topic; Drug Discovery; Humans; Lymphoma, Large B-Cell, Diffuse; Melphalan; Multiple Myeloma; Phenylalanine; Receptors, Antigen, T-Cell	2022
Melflufen for multiple myeloma: a promise unfulfilled? The Lancet. Haematology, 2022, Volume: 9, Issue:2 Topics: Humans; Melphalan; Multiple Myeloma; Phenylalanine	2022
Melflufen in multiple myeloma: the conclusion matters - Authors' reply. The Lancet. Haematology, 2022, Volume: 9, Issue:4 Topics: Humans; Melphalan; Multiple Myeloma; Phenylalanine	2022
Melflufen in multiple myeloma: the conclusion matters. The Lancet. Haematology, 2022, Volume: 9, Issue:4 Topics: Humans; Melphalan; Multiple Myeloma; Phenylalanine	2022
Growth Response and Differentiation of Bone Marrow-Derived Mesenchymal Stem/Stromal Cells in the Presence of Novel Multiple Myeloma Drug Melflufen. Cells, 2022, 05-07, Volume: 11, Issue:9 Topics: Bone Marrow; Bortezomib; Doxorubicin; Humans; Melphalan; Mesenchymal Stem Cells; Multiple Myeloma; Phenylalanine	2022
Melflufen for the treatment of multiple myeloma. Expert review of clinical pharmacology, 2022, Volume: 15, Issue:4 Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Europe; Melphalan; Multiple Myeloma; Phenylalanine	2022
A rapid intracellular enrichment of alkylating payload is essential for melphalan flufenamide potency and mechanism of action. Biochemical and biophysical research communications, 2023, 05-14, Volume: 656 Topics: Antineoplastic Agents, Alkylating; Humans; Melphalan; Multiple Myeloma; Phenylalanine	2023
Melflufen: post-hoc subgroup analyses and the US FDA Oncologic Drugs Advisory Committee. The Lancet. Haematology, 2023, Volume: 10, Issue:5 Topics: Advisory Committees; Humans; Medical Oncology; Melphalan; Phenylalanine; United States	2023